| Gene symbol | FLT3 | Synonyms | CD135, FLK-2, FLK2, STK1 | Type of gene | protein-coding |
| Chromosome | 13 | Map location | 13q12.2 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | fms related receptor tyrosine kinase 3 | ||||
| GTO ID | GTC3086 |
| Trial ID | NCT05432401 |
| Disease | Acute Myeloid Leukemia |
| Altered gene | FLT3 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | TAA05 Injection |
| Phase | Early_Phase1 |
| Recruitment status | Recruiting |
| Title | TAA05 Injection in the Treatment of Adult Patients With FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia |
| Year | 2022 |
| Country | China |
| Company sponsor | PersonGen BioTherapeutics (Suzhou) Co., Ltd. |
| Other ID(s) | PG-pCART-TAA05-001 |
| Cohort 1 | |||||||||
|
|||||||||